Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of November 2021, with a specific reporting date of November 12, 2021. The document serves as a transaction notification regarding insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) and Persons Closely Associated (PCAs) under the Company's Share Reward Plan.
Key Financial Metrics
The filing does not contain consolidated financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. It exclusively details specific share acquisition transactions.
| Transaction Date | Instrument | Price per Share | Total Volume per Executive | Exchange |
|---|---|---|---|---|
| 2021-11-09 | Ordinary Shares (25p each) | £15.6293 | 16 Shares (8 partnership + 8 matching) | London Stock Exchange (XLON) |
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document represents routine compliance disclosures for executive share acquisitions rather than a report on operational or financial variances compared to prior periods.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a statutory notification of transactions executed on November 9, 2021, involving the following executives:
- Ms E Walmsley (Chief Executive Officer)
- Mr R Connor (President, Vaccines & Global Health)
- Ms D Conrad (SVP, Human Resources)
- Mr J Ford (SVP and General Counsel)
- Ms S Jackson (SVP, Global Communications and CEO Office) and Mr D Jackson (PCA)
- Mr D Redfern (Chief Strategy Officer)
- Mr R Simard (President, Pharmaceuticals Supply Chain)
- Mr P Thomson (President, Global Affairs)
- Ms D Waterhouse (CEO of ViiV Healthcare)
- Ms V Whyte (Company Secretary)
Investor Verification Checklist
- Verify that the share acquisitions were executed in compliance with the Company's Share Reward Plan rules.
- Confirm the transaction price of £15.6293 aligns with the market price on the London Stock Exchange for November 9, 2021.
- Note that this filing does not provide updated financial performance data; refer to the most recent Form 20-F or quarterly earnings release for financial metrics.
- Ensure the total volume of 16 shares per executive (comprising partnership and matching shares) is consistent with the company's equity incentive policies.